The unprecedented public health and economic impact of the COVID-19 pandemic caused
by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been …

Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …

Abstract SARS-CoV-2 Omicron subvariants BA. 2.12. 1 and BA. 4/5 have surged notably to
become dominant in the United States and South Africa, respectively,. These new …

SARS-CoV-2 mRNA vaccination induces robust humoral and cellular immunity in the
circulation; however, it is currently unknown whether it elicits effective immune responses in …

The severe acute respiratory syndrome coronavirus 2 Omicron BA. 1 sublineage has been
supplanted in many countries by the BA. 2 sublineage. BA. 2 differs from BA. 1 by about 21 …

Abstract The SARS-CoV-2 B. 1.1. 529 (Omicron) variant contains 15 mutations of the
receptor-binding domain (RBD). How Omicron evades RBD-targeted neutralizing antibodies …

Abstract The SARS-CoV-2 Omicron variant was first identified in November 2021 in
Botswana and South Africa,–. It has since spread to many countries and is expected to …

Abstract The B. 1.1. 529/Omicron variant of SARS-CoV-2 was only recently detected in
southern Africa, but its subsequent spread has been extensive, both regionally and globally …

Summary The coronavirus disease 2019 (COVID-19) pandemic continues worldwide with
many variants arising, some of which are variants of concern (VOCs). A recent VOC, omicron …

Omicron is the evolutionarily most distinct severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) variant of concern (VOC) to date. We report that Omicron BA. 1 breakthrough …